SYSTEMATIC REVIEW OF DESIGN OF LATEST REAL-WORLD OBSERVATIONAL STUDIES IN MULTIPLE MYELOMA

被引：0
|
作者：
Aggarwal, S. [1 ]
Topaloglu, H. [1 ]
机构：
[1] NOVEL Hlth Strategies, Chevy Chase, MD USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1662
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN40
引用
收藏
页码：A140 / A141
页数：2
相关论文
共 50 条
  • [1] REAL-WORLD EFFECTIVENESS OF MONOCLONAL ANTIBODIES FOR PATIENTS WITH MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW
    Lai, J. H.
    Kenawy, A. S.
    Aiyeolemi, A. A.
    Russo, A. J.
    Sohn, T. J.
    Chen, S.
    Rascati, K. L.
    Avancena, A. L., V
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S37 - S37
  • [2] Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence
    Hartley-Brown, Monique A.
    Weisel, Katja
    Bitetti, Jacopo
    Carter, John A.
    McNamara, Simon
    Purser, Molly
    Palumbo, Antonio
    Richardson, Paul G.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024,
  • [3] IDENTIFYING REAL-WORLD DATA FOR OBSERVATIONAL STUDIES: A SYSTEMATIC APROACH
    Smoyer-Tomic, K. E.
    Young, K. C.
    Winchester, C.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A189 - A189
  • [4] Real-World Outcomes for the Treatment of Relapsed/Refractory Multiple Myeloma With Daratumumab: A Systematic Literature Review
    Gros Otero, B.
    Gungor, G.
    Gruppe, T. L.
    Wan, M.
    Jenkins, C.
    Helme, K.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S494 - S494
  • [5] TURNING THE TABLES TO ADDRESS THE REAL VALUE OF REAL-WORLD OBSERVATIONAL STUDIES OF NOVEL ANTI-CANCER AGENTS IN MULTIPLE MYELOMA
    Gaultney, J. G.
    Franken, M. G.
    Redekop, W. K.
    Huijgens, P. C.
    Uyl-de Groot, C. A.
    Sonneveld, P.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A460 - A460
  • [6] A SYSTEMATIC LITERATURE REVIEW ON THE USE OF REAL-WORLD EVIDENCE IN NICE TECHNOLOGY APPRAISALS INDICATED FOR MULTIPLE MYELOMA
    Dempsey, J.
    Tsang, C.
    Duffield, C.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S520 - S520
  • [7] Leveraging Real-World Evidence and Observational Studies in Treating Multiple Sclerosis
    Aboseif, Albert
    Roos, Izanne
    Krieger, Stephen
    Kalincik, Tomas
    Hersh, Carrie M.
    [J]. NEUROLOGIC CLINICS, 2024, 42 (01) : 203 - 227
  • [8] Belantamab mafodotin for relapsed/refractory multiple myeloma: a real-world observational study update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S185 - S186
  • [9] Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review
    Montalban, Xavier
    Matthews, Paul M.
    Simpson, Alex
    Petrie, John L.
    Sammon, Cormac
    Ramagopalan, Sreeram
    Disanto, Giulio
    Kuhle, Jens
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2023, 10 (03): : 302 - 311
  • [10] Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S504
12345